scholarly journals Multiple Myeloma Patients Treated at Academic Centers have Improved Survival Outcomes

2021 ◽  
Author(s):  
Victoria A. Vardell ◽  
Daniel A. Ermann ◽  
Srinivas K. Tantravahi ◽  
Brian McClune ◽  
Mary Nicole Steinbach ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Survival Outcomes

scholarly journals The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma

2020 ◽  
Vol 13 (12) ◽  
pp. 451
Author(s):  
Elena Zamagni ◽  
Paola Tacchetti ◽  
Paola Deias ◽  
Francesca Patriarca
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibodies ◽  
Immune System ◽  
Survival Outcomes ◽  
Newly Diagnosed ◽  
Cellular Targets ◽  
Recent Introduction

The recent introduction of monoclonal antibodies (MoAbs), with several cellular targets, such as CD-38 (daratumumab and isatuximab) and SLAM F7 (elotuzumab), differently combined with other classes of agents, has significantly extended the outcomes of patients with multiple myeloma (MM) in different phases of the disease. Initially used in advanced/refractory patients, different MoAbs combination have been introduced in the treatment of newly diagnosed transplant eligible patients (NDTEMM), showing a significant improvement in the depth of the response and in survival outcomes, without a significant price in terms of toxicity. In smoldering MM, MoAbs have been applied, either alone or in combination with other drugs, with the goal of delaying the progression to active MM and restoring the immune system. In this review, we will focus on the main results achieved so far and on the main on-going trials using MoAbs in SMM and NDTEMM.

scholarly journals Clinical Impact of 18f-FDG PET/CT As a Valuable Prognostic Tool for the Newly Diagnosed Multiple Myeloma with Extramedullary Disease

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 3142-3142
Author(s):  
Dong Won Baek ◽  
Hee Jeong Cho ◽  
Sang Kyun Sohn ◽  
Sung-Hoon Jung ◽  
Hong chae Moon ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Fdg Pet ◽  
Survival Outcomes ◽  
Newly Diagnosed ◽  
Prognostic Tool ◽  
Pet Ct ◽  
National University ◽  
18F Fdg ◽  
Fdg Pet Ct

Purpose 18F-FDG PET/CT (PET/CT) could be a valuable tool to predict long-term survival outcomes in patients with newly diagnosed multiple myeloma (MM). It has ability to distinguish metabolically active sites such as extramedullary disease (EMD) as well as bone damage with relatively high sensitivity and specificity. In this study, we attempted to evaluate the role of PET-CT as a novel prognostic tool for patients with newly diagnosed MM who have EMD. Patients and Methods This study included 211 patients who were newly diagnosed with multiple myeloma from Kyunpook National University Hospital and Chonnam National University Hwasun Hospital. We retrospectively analyzed the medical records of enrolled patients. PET/CT was performed at the diagnosis and EMD was identified in 36 patients (17.1%). Results With a median follow-up duration of 21.5 months (range 1.4-67.7), the estimated 2-year PFS and OS rates were 46.1% and 79.6%, respectively. The presence of PET/CT positive EMD and high maximum standardized uptake value (SUVmax) on baseline PET/CT were significantly associated with inferior long-term survivals in terms of PFS (p=0.013, p=0.007) and OS (p=0.002, p=0.004). In addition, patients who underwent autologous stem cell transplantation (auto-SCT) showed superior PFS (p=0.005) and OS (p=0.022) in PET/CT positive EMD group. Meanwhile, Revised-International Staging System (R-ISS) successfully predicted the prognosis in this study. When we modified R-ISS with the presence of EMD, survival outcomes of the R-ISS stage III patients who didn't have EMD were similar to R-ISS II, while patients with PET/CT positive EMD showed even worse prognosis than the R-ISS stage III group. In the multivariate survival analysis, the presence of EMD (hazard ratio (HR), 2.397; 95% confidence internal (CI), 1.281-4.483; p=0.006) and auto-SCT (HR, 0.326; 95% CI, 0.194-0.549; p<0.001) were related to PFS, while LDH (HR, 2.56; 95% CI, 1.221-5.366; p=0.013) level and auto-SCT (HR, 0.398; 95% CI, 0.167-0.953; p=0.039) were independent prognostic factors of OS. Conclusion In conclusion, PET/CT positive EMD was a poor prognostic factor in patients with newly diagnosed MM. In addition, PET/CT could be a valuable tool to make better risk-adapted treatment strategies with R-ISS in EMD positive MM patients. Above all, patients with PET/CT positive EMD should be considered auto-SCT to improve long-term survivals. Figure Disclosures No relevant conflicts of interest to declare.

Abstract 4913: Differences in presentation and survival outcomes for African American patients with newly diagnosed multiple myeloma

2019 ◽  
Author(s):  
Nisha Joseph ◽  
Vikas A. Gupta ◽  
Craig Hofmeister ◽  
Charise Gleason ◽  
Leonard T. Heffner ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
African American ◽  
Survival Outcomes ◽  
Newly Diagnosed

Secondary Adrenal Insufficiency Is Associated with Poor Survival Outcomes in Multiple Myeloma

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5631-5631
Author(s):  
Seo-Yeon Ahn ◽  
Sung-Hoon Jung ◽  
Hee Kyung Kim ◽  
Ho-Cheol Kang ◽  
Deok-Hwan Yang ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Adrenal Insufficiency ◽  
Clinical Significance ◽  
Predictive Factors ◽  
Conflicts Of Interest ◽  
Hospitalized Patients ◽  
Survival Outcomes ◽  
Secondary Adrenal Insufficiency ◽  
Poor Survival ◽  
Acth Stimulation

Abstract Background: Glucocorticoids has been a backbone of various treatment regimens for multiple myeloma (MM). The repeated and chronic use of high doses of glucocorticoids is associated with development of secondary adrenal insufficiency (AI), and AI could be a major problem in critically-ill patients. However, there has been no specialized data about incidence and clinical significance of secondary AI in hospitalized patients with MM. Purpose: The objective of this retrospective study is to evaluate incidence, predictive factors, and clinical significance of secondary AI in hospitalized patients with MM. Methods: We retrospectively evaluated medical records of MM patients who were hospitalized in Chonnam National University Hwasun Hospital, South Korea from December 2014 to December 2015. The definite AI was diagnosed when the peak cortisol concentration was less than < 500 nmol/L (18 mcg/dL) after ACTH administration. Results: Between December 2014 and December 2015, 77 patients were hospitalized, and 58 underwent rapid ACTH stimulation test. The most frequent cause of hospitalization was infection (70.7%), followed by weakness (24.1%), and the others (5.3%). The definite AI was confirmed in 19 patients (32.7%). To evaluate the predictive factors of AI, all variables including clinical characteristics, laboratory results, cumulative steroid dose, and treatment duration at hospitalization were analyzed, but there were no significant predictors for AI. In addition, the patients with AI had a significantly poor survival outcomes compared to those without AI (the median overall survival of 42.3 months vs. 82.7 months; P = 0.037) (Figure 1). Conclusions: This study showed that the secondary AI is not a rare condition among hospitalized patients with MM, and there was no specific predictable symptoms or signs. In addition, development of AI in the treatment period is associated with a poor prognosis. This study suggests that evaluation of AI is routinely needed in hospitalized patients with MM. Disclosures No relevant conflicts of interest to declare.

Measurable (Minimal) Residual Disease—A Meaningful Biomarker in Multiple Myeloma

2016 ◽  
Vol 12 (02) ◽  
pp. 75
Author(s):  
Manisha Bhutani ◽  
Saad Z Usmani ◽  
◽  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Trials ◽  
Residual Disease ◽  
Scientific Evidence ◽  
Survival Outcomes ◽  
Sequencing Technologies ◽  
Therapeutic Decisions ◽  
Meta Analyses ◽  
Minimal Residual ◽  
Measurable Residual Disease

Individual studies and meta-analyses highlight superior survival outcomes among those multiple myeloma patients achieving measurable residual disease (MRD) negative status. With the availability of next-generation flow cytomery and sequencing technologies, it is realistically possible to track MRD response in every patient. As the scientific evidence mounts, MRD is being established as a desired end-point for clinical trials. Future efforts should be directed at validating MRD as a surrogate biomarker for developing curative strategies and determining how MRD can be used to guide therapeutic decisions.

scholarly journals Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients

Cancer ◽  
2014 ◽  
Vol 121 (6) ◽  
pp. 853-862 ◽  
Author(s):  
Meagan S. Barbee ◽  
Ajay Nooka ◽  
Jonathan L. Kaufman ◽  
Sungjin Kim ◽  
Zhengjia Chen ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 1 ◽  
Survival Outcomes ◽  
Refractory Multiple Myeloma

scholarly journals Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma

2011 ◽  
Vol 6 ◽  
pp. CMO.S7275 ◽  
Author(s):  
Adrian Alegre ◽  
Isabel Vicuña ◽  
Beatriz Aguado
Keyword(s):  
Multiple Myeloma ◽  
Venous Thromboembolism ◽  
Survival Outcomes ◽  
Second Primary ◽  
Safety And Efficacy ◽  
Depth Of Response ◽  
Increased Risk ◽  
First Relapse ◽  
Immunomodulatory Drug ◽  
Second Primary Malignancies

Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared with dexamethasone alone in patients with relapsed or refractory MM (RRMM). Clinical benefit may be greatest when Len+Dex is given at first relapse, and continued treatment appears to provide greater depth of response and improved survival outcomes. The most common adverse events associated with Len+Dex are cytopenias, which are predictable and manageable. Len+Dex is associated with an increased risk of venous thromboembolism, which necessitates adequate prophylaxis. The risk of second primary malignancies does not appear to be increased in patients with RRMM treated with lenalidomide-based therapy. Here we review the safety and efficacy of Len+Dex in RRMM, and provide an overview of data from Spain on the use of Len+Dex in RRMM.

Sign in / Sign up

Export Citation Format

Share Document